Despite great GBM trial results CHM couldn't find anyone to partner / buy it. Despite the support from Penn the CDH 17 trial can't get any $$$ either and even Dr Bec's " friends " , who are in the know, have hesitations.
Why? Maybe today's IMU statement gave the answer away as not just IMU but others too waste no time to highlight the advantages of allogeneic over autologous CAR-Ts. CHM got the 2 AML NK-trials which are based on allogeneic and got good results so far. But the space is overcrowded with more than 300 comps world wide trying to develop their CAR-Ts. IMU seems to be the very first to get an allogeneic over the approval line but even that hasn't attracted any big fund or pharma. In the end great results are the base for any deal but at this stage it seems even great results won't get the funding required because when looking over to the US the hottest oncology field atm is the radio pharma space. CAR-T works, no doubt, but too expensive and complicated. Other new techs have more advantages.
And that could explain why CHM struggles. Dr Bec tries to achieve the impossible, good on her. There is still a chance for success but just a very tiny one.
GLTA
CHM Price at posting:
1.1¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)